



January 24, 2020

GE Healthcare Finland Oy  
Joel Kent  
Senior Regulatory Affairs Manager  
Kuortaneenkatu 2  
00510 Helsinki  
Finland

Re: K191249

Trade/Device Name: CARESCAPE B450

Regulation Number: 21 CFR 870.1025

Regulation Name: Arrhythmia Detector and Alarm (Including ST-Segment Measurement and Alarm)

Regulatory Class: Class II

Product Code: MHX, BZK, BZL, BZQ, CAP, CBQ, CBR, CBS, CCK, CCL, DPS, DPZ, DQA, DQK,  
DRT, DSI, DSJ, DSK, DXG, DXN, FLL, GWJ, GWQ, KOI, KRB, MLD, NHO,  
NHP, NHQ, OLT, OLW, OMC, ORT

Dated: December 20, 2019

Received: December 23, 2019

Dear Joel Kent:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jennifer Shih  
Assistant Director (Acting)  
Division of Cardiac Electrophysiology,  
Diagnostics and Monitoring Devices  
Office of Cardiovascular Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)

K191249

Device Name

CARESCAPE B450

Indications for Use (Describe)

The CARESCAPE B450 is a multi-parameter patient monitor intended for use in multiple areas and intra hospital transport within a professional healthcare facility.

The CARESCAPE B450 is intended for use on adult, pediatric, and neonatal patients and on one patient at a time.

The CARESCAPE B450 is indicated for monitoring of:

- hemodynamic (including ECG, ST segment, arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation),
- respiratory (impedance respiration, airway gases (CO<sub>2</sub>, O<sub>2</sub>, N<sub>2</sub>O, and anesthetic agents), spirometry, gas exchange), and
- neurophysiological status (including electroencephalography, Entropy, Bispectral Index (BIS), and neuromuscular transmission).

The CARESCAPE B450 can be a stand-alone monitor or interfaced to other devices. It can also be connected to other monitors for remote viewing and to data management software devices via a network.

The CARESCAPE B450 is able to detect and generate alarms for ECG arrhythmias: atrial fibrillation, accelerated ventricular rhythm, asystole, bigeminy, bradycardia, ventricular couplet, irregular, missing beat, multifocal premature ventricular contractions (PVCs), pause, R on T, supra ventricular tachycardia, tachycardia, trigeminy, ventricular bradycardia, ventricular fibrillation/ventricular tachycardia, ventricular tachycardia, and VT>2. The CARESCAPE B450 also shows alarms from other ECG sources.

The CARESCAPE B450 also provides other alarms, trends, snapshots and events, and calculations, and can be connected to displays, printers and recording devices.

The CARESCAPE B450 is intended for use under the direct supervision of a licensed healthcare practitioner, or by personnel trained in proper use of the equipment in a professional healthcare facility.

Contraindications for using the monitor

The CARESCAPE B450 is not intended for use in a controlled MR environment.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

---

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
*PRAStaff@fda.hhs.gov*

*“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”*



GE Healthcare Finland Oy  
Kuortaneenkatu 2  
00510 Helsinki  
Finland  
T: +358 10 39411

### 510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

Owner/Contact/Date (807.92(a)(1)):

Date: January 21, 2019  
Owner/Submitter: GE Healthcare Finland Oy.  
Kuortaneenkatu 2  
00510 Helsinki  
FINLAND  
Phone: +358 10 39411

Primary Contact Person: Joel Kent  
Senior Regulatory Affairs Manager  
GE Healthcare  
Phone: 617-851-0943  
  
E-mail: joel.kent@ge.com

Secondary Contact Person: Anssi Ruokonen  
Regulatory Affairs Leader  
GE Healthcare Finland Oy  
Kuortaneenkatu 2  
00510 Helsinki  
Finland  
  
Phone: + 358 10 394 3686

E-mail: Anssi.ruokonen@ge.com

Device names (807.92(a)(2)):

Trade Name: CARESCAPE B450  
Common/Usual Name: Multiparameter patient monitor (monitor, physiological, patient (with arrhythmia detection or alarms))

Classification Names: 21 CFR 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm)  
21 CFR 868.1850 spirometer, monitoring (w/wo alarm)  
21 CFR 868.1730 computer, oxygen-uptake  
21 CFR 868.2375 monitor, breathing frequency  
21 CFR 868.2600 monitor, airway pressure (includes gauge and/or alarm)  
21 CFR 868.1500 analyzer, gas, enflurane, gaseous-phase (anesthetic conc.)  
21 CFR 868.1500 analyzer, gas, desflurane, gaseous-phase (anesthetic conc.)  
21 CFR 868.1500 analyzer, gas, sevoflurane, gaseous-phase (anesthetic conc.)  
21 CFR 868.1500 analyzer, gas, isoflurane, gaseous-phase (anesthetic conc.)  
21 CFR 868.1700 analyzer, gas, nitrous-oxide, gaseous phase (anesthetic conc.)  
21 CFR 868.1620 analyzer, gas, halothane, gaseous-phase (anesthetic conc.)  
21 CFR 868.1400 analyzer, gas, carbon-dioxide, gaseous-phase  
21 CFR 868.1720 analyzer, gas, oxygen, gaseous-phase  
21 CFR 870.2340 electrocardiograph  
21 CFR 870.2710 oximeter, ear  
21 CFR 870.2700 oximeter  
21 CFR 870.1425 computer, diagnostic, programmable  
21 CFR 870.2300 monitor, cardiac (incl. cardiometer & rate alarm)  
21 CFR 870.1025 detector and alarm, arrhythmia  
21 CFR 870.1100 alarm, blood-pressure  
21 CFR 870.1110 computer, blood-pressure  
21 CFR 870.1435 computer, diagnostic, pre-programmed, single-function  
21 CFR 870.1130 system, measurement, blood-pressure, non-invasive  
21 CFR 870.2910 thermometer, electronic, clinical  
21 CFR 882.1900 stimulator, auditory, evoked response  
21 CFR 882.1400 full-montage standard electroencephalograph  
21 CFR 868.2775 stimulator, nerve, peripheral, electric  
21 CFR 870.1915 probe, thermodilution  
21 CFR 870.1025 monitor, st segment with alarm  
21 CFR 882.1400 non-normalizing quantitative electroencephalograph software  
21 CFR 882.1400 index-generating electroencephalograph software  
21 CFR 882.1400 reduced- montage standard electroencephalograph

K191249 CARESCAPE B450

21 CFR 882.1400 burst suppression detection software for electroencephalograph

Product Code: MHX

Subsequent Product Codes: BZK, BZL, BZQ, CAP, CBQ, CBR, CBS, CCK, CCL, DPS, DPZ, DQA, DQK, DRT, DSI, DSJ, DSK, DXG, DXN, FLL, GWJ, GWQ, KOI, KRB, MLD, NHO, NHP, NHQ, OLT, OLW, OMC, ORT

Predicate Device(s) Primary predicate:  
(807.92(a)(3): K132533 CARESCAPE Monitor B450  
Additional predicates:  
K131414 CARESCAPE Monitor B850  
K131223 CARESCAPE Monitor B650

Device Description  
(807.92(a)(4)):

CARESCAPE B450 V3 is a new version of a portable multi-parameter patient monitoring system. The CARESCAPE B450 V3 includes the monitor itself with built-in CPU, power unit, a 12 inch touch display, the CARESCAPE Software version 3 and one or two batteries. CARESCAPE B450 V3 is equipped with so called ePort interface that supports use of PDM or CARESCAPE ONE patient data acquisition modules for patient monitoring. CARESCAPE B450 V3 is also equipped with one module slot where patient data acquisition modules (E-Modules), can be connected to perform patient monitoring. The CARESCAPE B450 V3 includes features and subsystems that are optional or configurable.

Intended Use: (807.92(a)(5)):

*Indications (from labeling)*

The CARESCAPE B450 is a multi-parameter patient monitor intended for use in multiple areas and intra hospital transport within a professional healthcare facility.

The CARESCAPE B450 is intended for use on adult, pediatric, and neonatal patients and on one patient at a time.

The CARESCAPE B450 is indicated for monitoring of:

- hemodynamic (including ECG, ST segment, arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation),
- respiratory (impedance respiration, airway gases (CO<sub>2</sub>, O<sub>2</sub>, N<sub>2</sub>O, and anesthetic agents), spirometry, gas exchange), and
- neurophysiological status (including electroencephalography, Entropy, Bispectral Index (BIS), and neuromuscular transmission).

The CARESCAPE B450 can be a stand-alone monitor or interfaced to other devices. It can also be connected to other monitors for remote viewing and to data management software devices via a network.

The CARESCAPE B450 is able to detect and generate alarms for ECG arrhythmias: atrial fibrillation, accelerated ventricular rhythm, asystole, bigeminy, bradycardia, ventricular couplet, irregular, missing beat, multifocal premature ventricular contractions (PVCs), pause, R on T, supra ventricular tachycardia, tachycardia, trigeminy, ventricular bradycardia, ventricular fibrillation/ventricular tachycardia, ventricular



tachycardia, and VT>2. The CARESCAPE B450 also shows alarms from other ECG sources.

The CARESCAPE B450 also provides other alarms, trends, snapshots and events, and calculations, and can be connected to displays, printers and recording devices.

The CARESCAPE B450 is intended for use under the direct supervision of a licensed healthcare practitioner, or by personnel trained in proper use of the equipment in a professional healthcare facility.

### **Contraindications for using the monitor**

The CARESCAPE B450 is not intended for use in a controlled MR environment.

Technology (807.92(a)(6)): The CARESCAPE B450 with CARESCAPE Software version 3 incorporates updated hardware and a new software platform.

The fundamental function and operation of the proposed CARESCAPE B450 V3 monitor is unchanged compared to CARESCAPE Monitor B450 with ESP V2 software (K132533). All monitored parameters are identical compared to the predicate except now we have added support for gas exchange parameters in the CARESCAPE B450 V3 indications for use. In 2015 the single-width gas module that includes gas exchange parameters received clearance in CARESCAPE Respiratory Modules, E-sCO, E-sCOV, E-sCOVX, E-sCAiO, E-sCAiOV, E-sCAiOVX (K150245). As a result, when using the E-sCOVX or E-sCAiOVX modules with gas exchange option and the CARESCAPE B450 V3 we can enable monitoring of O2 consumption (VO2), CO2 production (VCO2), energy expenditure (EE) and respiratory quotient (RQ). These gas exchange parameters are not new to our product line as they are present already in both the predicate CARESCAPE Monitor B850 (K131414) and CARESCAPE Monitor B650 (K131223).

A summary of the main changes compared to the predicate are listed below in the comparison table.

### Subject Device and Predicate Device Comparison

Specification	CARESCAPE Monitor B450 with ESP V2 software (K132533)	CARESCAPE B450 with CSP software version V3	Differences
<b>Patient type</b>	Adult, pediatric & neonatal	Adult, pediatric & neonatal	Identical
<b>Use environments</b>	Within a professional healthcare facility (Not intended for MRI)	Within a professional healthcare facility (Not intended for MRI)	Identical
<b>Size (H x W x D) &amp; Weight</b>	290 x 310 x 160 mm (11.4 x 12.1 x 6.2 in) and 4.7 kg (10.4 lbs) with batteries but without modules	290 x 310 x 160 mm (11.4 x 12.1 x 6.2 in) and weight 4.7 kg (10.4 lbs) with batteries but without modules	Identical
<b>Processor</b>	Intel Atom Z510 1,1GHz	Freescall ARM Cortex-A9	Equivalent The CARESCAPE Bx50 V3 monitors have an updated common CPU platform.
<b>Module Housing</b>	One optional E-module slots and optional recorder. One slide mount for acquisition module	One optional E-module slots and optional recorder. One slide mount for acquisition module	Identical
<b>Display/screen</b>	12" Active matrix color TFT LCD	12" Active matrix color TFT LCD	Identical
<b>Waveforms and parameter windows</b>	Standard view: Up to 6 individual waveforms and up to 16 parameter windows, if horizontal parameter area turned on	Standard view: Up to 6 individual waveforms and up to 16 parameter windows, if horizontal parameter area turned on	Identical
<b>Modules</b>	E-PSM; E-PSMP, E-miniC, E-P, E-PP, E-PT, E-COP, E-COPsv, E-EEG, E-Entropy, E-NMT, E-BIS, E-NSAT, E-NSATX, E-Masimo, E-sCO, E-sCAiO, E-sCOV, E-sCAiOV, E-PicCO, PDM	E-BIS, E-COP, E-COPsv, E-PicCO, E-EEGX, E-Entropy, E-Masimo, E-miniC, E-NMT, E-NSATX, E-PP, E-PT, E-sCAiO, E-sCAiOE, E-sCAiOV, E-sCAiOVX, E-sCAiOVE, E-sCO, E-sCOV, E-sCOVX, PDM, CARESCAPE ONE	Equivalent Removed support for several legacy E/M multiparameter hemodynamic acquisition modules as many newer acquisition modules are included, covering the same parameters. Added support for CARESCAPE ONE and E-EEGX acquisition modules. Added support for E-sCAiOVX and E-sCOVX modules (K150245).

Specification	CARESCAPE Monitor B450 with ESP V2 software (K132533)	CARESCAPE B450 with CSP software version V3	Differences
<b>Available parameters</b>	ECG, ST segment, arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation, impedance respiration, airway gases (CO <sub>2</sub> , O <sub>2</sub> , N <sub>2</sub> O, and anesthetic agents), spirometry, electroencephalography, Entropy, Bispectral Index (BIS), neuromuscular transmission.	ECG, ST segment, arrhythmia detection, ECG diagnostic analysis and measurement, invasive pressure, non-invasive blood pressure, pulse oximetry, cardiac output (thermodilution and pulse contour), temperature, mixed venous oxygen saturation, and central venous oxygen saturation, impedance respiration, airway gases (CO <sub>2</sub> , O <sub>2</sub> , N <sub>2</sub> O, and anesthetic agents), spirometry, gas exchange, electroencephalography, Entropy, Bispectral Index (BIS), neuromuscular transmission.	Added support for gas exchange parameters in the CARESCAPE B450 V3 indications for use. These gas exchange parameters are not new to our product line as they are present already in both the predicate CARESCAPE Monitor B850 (K131414) and CARESCAPE Monitor B650 (K131223). The reason for not including these in the predicate CARESCAPE Monitor B450 (K132533) was simply a limitation because at the time (2013) the older gas modules that allowed gas-exchange were double-width size and these size modules only fit in the predicate B650 and B850 monitors but not in the predicate B450 which only has a single-width E-module slot. In 2015 the single-width gas module that includes gas exchange parameters received clearance in CARESCAPE Respiratory Modules, E-sCO, E-sCOV, E-sCOVX, E-sCAiO, E-sCAiOV, E-sCAiOVX (K150245). As a result, when using the E-sCOVX or E-sCAiOVX modules with gas exchange option and the CARESCAPE B450 V3 we can enable monitoring of O <sub>2</sub> consumption (VO <sub>2</sub> ), CO <sub>2</sub> production (VCO <sub>2</sub> ), energy expenditure (EE) and respiratory quotient (RQ). The gas exchange parameters and calculations are identical to the predicate CARESCAPE Monitor B850 (K131414) and CARESCAPE Monitor B650 (K131223) monitors.

<b>Specification</b>	<b>CARESCAPE Monitor B450 with ESP V2 software (K132533)</b>	<b>CARESCAPE B450 with CSP software version V3</b>	<b>Differences</b>
<b>EK-Pro arrhythmia detection algorithm</b>	EK-Pro V13	EK-Pro V14	Equivalent CARESCAPE B450 V3 uses an EK-ProV14 arrhythmia analysis algorithm compared to the EK-Pro V13 used in the predicate monitors
<b>Graphical user interface</b>	GE Healthcare Common User Interface (CUI) Requirements and Style Versio 6	GE Healthcare HDX	A new color scheme for the display and slight visual adjustments have been incorporated, in line with a GE Healthcare wide user interface design guideline. The overall user interface layout, structure, operations, and workflow remains the same as the predicate.
<b>Printing</b>	Built-in or central and networked laser printer Printings for waveforms, alarms waveforms, numeric trends	Built-in or central and networked laser printer Printings for waveforms, alarms waveforms, numeric trends	Identical
<b>Mounting options</b>	Multiple GCX mounting systems, Roll Stand, Quick Mount, Bed Rail Hooks	Multiple GCX mounting systems, Roll Stand, Quick Mount, Bed Rail Hooks	Identical
<b>Alarms</b>	Alarm management core functionalities: Classification and notification of alarms Adjustment of alarm settings Alarm On/Off functionality and audio silencing	Alarm management core functionalities: Classification and notification of alarms Adjustment of alarm settings Possibility to set critical alarm limits Alarm On/Off functionality and audio silencing	Equivalent The predicate already included the options to configure some alarm settings. In V3, more flexibility was added for the user to adjust alarm priorities and alarm criteria for additional parameter alarms, including additional alarm delay options, critical alarm options, alarm acknowledgement and latched alarm indicators, and a pause monitoring & central function. In general, options for tailored/specific alarm management schemes have been added supporting clinicians in their goals of reducing alarm fatigue while maintaining safety. Default setting are according to IEC 60601-1-8.

Specification	CARESCAPE Monitor B450 with ESP V2 software (K132533)	CARESCAPE B450 with CSP software version V3	Differences
<b>Remote Alarm Device</b>	Alarm Interface of ESP V2 SW was not utilized	Alarm Interface to the Remote Alarm Device, CARESCAPE RAD	Equivalent The predicate device did not support the connector type of the Remote Alarm Box with Remote Light (RAB RL). Therefore, the Alarm Interface of ESP V2 could not be utilized. The CARESCAPE RAD is the new USB accessory for use with the CARESCAPE Bx50 V3. As the proposed CARESCAPE B450 V3 provides USB connection, now the Alarm Interface of the CARESCAPE Bx50 V3 is utilized for remote alarming.  The CARESCAPE RAD is intended for relaying primary alarm signals from the host device to an external distributed alarm system, i.e. a nurse call system or a remote alarm light. The CARESCAPE Bx50 V3 alarm functionality is unaffected when using the CARESCAPE RAD as the new accessory simply receives data from the monitor (one-way communication) to indicate when an alarm is active or not.
<b>Intrahospital transport within a professional healthcare facility.</b>	Yes	Yes	Identical
<b>Battery operation</b>	Rechargeable Lithium-Ion batteries	Rechargeable Lithium-Ion batteries	Identical
<b>Networking capability</b>	CARESCAPE Network LAN/VLAN Optional WLAN	CARESCAPE Network LAN/VLAN Single wire network configuration supported for CARESCAPE Networks Optional WLAN	Equivalent The single wire network configuration simplifies the installation and maintenance of CARESCAPE Bx50 V3 patient monitors. The single wire network configuration has no impact on clinical monitoring.
<b>Network interface</b>	10baseT, 100baseT, 802.11 abg IEEE 802.11r fast roaming is not supported.	10baseT, 100baseT, 802.11 abgn IEEE 802.11r fast roaming supported.	Equivalent Support wireless data transfer with support for WPA2-Enterprise security mechanisms using advanced authentication and data encryption for enhanced security, and support the IEEE 802.11n protocol for faster wireless data transfer, and the IEEE 802.11r fast roaming standard for fast and secure handoffs from one access point to another during intra-hospital transport.

Determination of  
Substantial Equivalence  
(807.92(b)(1)):

Summary of Non-Clinical Tests:

Summary of Non-Clinical Tests:

Bench testing related to software, hardware and performance including applicable consensus standards was conducted on the CARESCAPE B450, demonstrating the design meets the specifications.

The hardware bench testing included electromagnetic compatibility, electrical safety, environmental, WLAN, battery and usability.

The CARESCAPE B450 has been found to substantially equivalent to the predicate device(s) for the intended users, uses and use environments. Extensive usability work has been completed for CARESCAPE B450 and the predicate devices including critical task identification through use-based hazard analysis, multiple rounds of formative usability testing and summative testing, among other activities.

Software testing included software design, development, verification, validation and traceability.

Patient safety, security, and privacy risks have been addressed in the design and development of CARESCAPE B450 including a Security Risk Assessment and Threat model. This includes system integrity controls, access controls, audit controls, network controls, and remote service controls which map to the General Principles and Security Capabilities outlined in the FDA Guidance for Content of Premarket Submissions for Management of Cybersecurity in Medical Devices Guidance for Industry and Food and Drug Administration Staff Document issued on October 2, 2014.

The CARESCAPE B450 battery has been investigated by UL in accordance with the Standard for Safety of Household and commercial Batteries, UL 2054 and Standard for Safety of Information Technology Equipment-Safety-Part1: General Requirements, CAN/CSA-C22.2 No. 60950-1-07, and UL 60950-

1. The battery has been tested by UL and found to be in conformity with IEC 62133 ed.2. Secondary cells and batteries containing alkaline or other non-acid electrolytes - Safety requirements for portable sealed secondary cells, and for batteries made from them, for use in portable applications. Integration of the battery management with the new design has been successfully tested and concluded to be operating as specified

Testing was completed on CARESCAPE B450 to show the device can withstand network storm, i.e. continue to monitor patients without rebooting when connected by wire to either MC, IX, or both networks which suffer broadcast storm traffic.

Clinical (807.92(b)(2)): Summary of Clinical Tests:

The subject of this premarket submission, CARESCAPE B450 did not require clinical studies to support substantial equivalence.

Conclusion (807.92(b)(3)): GE Healthcare considers the CARESCAPE B450 to be substantially equivalent to the predicate device(s).